

# Alexander Y Walley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6299517/publications.pdf>

Version: 2024-02-01

150  
papers

6,987  
citations

81900  
39  
h-index

66911  
78  
g-index

151  
all docs

151  
docs citations

151  
times ranked

4798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. <i>BMJ</i> , The, 2013, 346, f174-f174.	6.0	734
2	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. <i>Annals of Internal Medicine</i> , 2018, 169, 137.	3.9	680
3	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 90-96.	2.8	233
4	Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. <i>International Journal of Drug Policy</i> , 2017, 46, 172-179.	3.3	225
5	Characteristics of Fentanyl Overdose â€” Massachusetts, 2014â€”2016. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 382-386.	15.1	219
6	Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose. <i>American Journal of Public Health</i> , 2009, 99, 788-791.	2.7	211
7	Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. <i>Obstetrics and Gynecology</i> , 2018, 132, 466-474.	2.4	209
8	Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers. <i>Journal of General Internal Medicine</i> , 2008, 23, 1393-1398.	2.6	192
9	Addiction consultation services â€” Linking hospitalized patients to outpatient addiction treatment. <i>Journal of Substance Abuse Treatment</i> , 2017, 79, 1-5.	2.8	161
10	A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming into Clinical Practice. <i>Substance Abuse</i> , 2015, 36, 240-253.	2.3	148
11	Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. <i>American Journal of Epidemiology</i> , 2014, 180, 673-686.	3.4	137
12	Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. <i>BMC Public Health</i> , 2014, 14, 297.	2.9	125
13	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. <i>American Journal of Public Health</i> , 2014, 104, e7-e9.	2.7	125
14	Opioid overdose prevention and naloxone rescue kits: what we know and what we donâ€™t know. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 4.	2.6	121
15	Opioid Education and Nasal Naloxone Rescue Kits in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2015, 16, 381-384.	1.1	116
16	Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S19-S27.e4.	1.5	116
17	Acute Care Hospital Utilization Among Medical Inpatients Discharged With a Substance Use Disorder Diagnosis. <i>Journal of Addiction Medicine</i> , 2012, 6, 50-56.	2.6	115
18	Touchpoints â€” Opportunities to predict and prevent opioid overdose: A cohort study. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107537.	3.2	113

#	ARTICLE	IF	CITATIONS
19	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	3.2	113
20	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. <i>American Journal of Public Health</i> , 2018, 108, 1675-1681.	2.7	109
21	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. <i>Drug and Alcohol Dependence</i> , 2019, 200, 59-63.	3.2	103
22	Opioid overdose prevention with intranasal naloxone among people who take methadone. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 241-247.	2.8	91
23	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. <i>Harm Reduction Journal</i> , 2015, 12, 25.	3.2	90
24	Prevention of Fatal Opioid Overdose. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1863.	7.4	88
25	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. <i>Academic Emergency Medicine</i> , 2014, 21, 1173-1177.	1.8	73
26	Knowledge of and interest in hepatitis C treatment at a methadone clinic. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 181-187.	2.8	70
27	Patient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment. <i>AIDS Patient Care and STDs</i> , 2014, 28, 71-81.	2.5	66
28	Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use–Associated Infective Endocarditis. <i>JAMA Network Open</i> , 2020, 3, e2016228.	5.9	65
29	Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. <i>International Journal of Drug Policy</i> , 2018, 54, 43-50.	3.3	64
30	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. <i>Drug and Alcohol Dependence</i> , 2009, 101, 101-106.	3.2	57
31	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. <i>Journal of Addiction Medicine</i> , 2016, 10, 300-308.	2.6	57
32	A scoping review of post opioid-overdose interventions. <i>Preventive Medicine</i> , 2019, 128, 105813.	3.4	54
33	Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011–2015. <i>Journal of General Internal Medicine</i> , 2018, 33, 1512-1519.	2.6	51
34	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.2	50
35	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
36	Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. <i>BMC Research Notes</i> , 2016, 9, 465.	1.4	49

#	ARTICLE	IF	CITATIONS
37	Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. <i>Addiction</i> , 2020, 115, 924-932.	3.3	46
38	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	2.2	43
39	Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. <i>International Journal of Drug Policy</i> , 2019, 68, 37-45.	3.3	43
40	Overdose Education and Naloxone Rescue Kits for Family Members of Individuals who Use Opioids: Characteristics, Motivations, and Naloxone Use. <i>Substance Abuse</i> , 2015, 36, 149-154.	2.3	41
41	HIV-infected individuals who use alcohol and other drugs, and virologic suppression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1129-1136.	1.2	41
42	Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose. <i>Journal of Urban Health</i> , 2019, 96, 367-378.	3.6	40
43	Rejection of Patients With Opioid Use Disorder Referred for Post-acute Medical Care Before and After an Anti-discrimination Settlement in Massachusetts. <i>Journal of Addiction Medicine</i> , 2021, 15, 20-26.	2.6	38
44	Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. <i>Journal of the International AIDS Society</i> , 2014, 17, 19043.	3.0	37
45	Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection. <i>Journal of Substance Abuse Treatment</i> , 2015, 59, 59-66.	2.8	37
46	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
47	Association between mortality rates and medication and residential treatment after inpatient medically managed opioid withdrawal: a cohort analysis. <i>Addiction</i> , 2020, 115, 1496-1508.	3.3	36
48	<scp>HERMITAGE</scp>â€”a randomized controlled trial to reduce sexually transmitted infections and <scp>HIV</scp> risk behaviors among <scp>HIV</scp>-infected <scp>R</scp>ussian drinkers. <i>Addiction</i> , 2015, 110, 80-90.	3.3	35
49	Methadone Dose, Take Home Status, and Hospital Admission Among Methadone Maintenance Patients. <i>Journal of Addiction Medicine</i> , 2012, 6, 186-190.	2.6	33
50	Effect of Age on Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011 to 2015. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 128-132.	2.6	33
51	Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e210-e218.	10.0	33
52	Against Medical Advice Discharges in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2484-e2492.	5.8	32
53	Expanding access to naloxone for family members: The Massachusetts experience. <i>Drug and Alcohol Review</i> , 2018, 37, 480-486.	2.1	30
54	Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012â€”2014. <i>Drug and Alcohol Dependence</i> , 2019, 194, 28-31.	3.2	30

#	ARTICLE	IF	CITATIONS
55	Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. <i>Annals of Emergency Medicine</i> , 2020, 75, 29-38.	0.6	29
56	Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 5.	2.6	28
57	The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. <i>Public Health Reports</i> , 2019, 134, 667-674.	2.5	27
58	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	3.2	25
59	Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014. <i>Public Health Reports</i> , 2016, 131, 671-675.	2.5	23
60	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <i>Postgraduate Medical Journal</i> , 2016, 92, 356-363.	1.8	22
61	Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia—A mixed methods study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20877.	3.0	21
62	Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waived prescriber supply. <i>Journal of Substance Abuse Treatment</i> , 2020, 115, 108032.	2.8	21
63	Nondisclosure of HIV Infection to Sex Partners and Alcohol's Role: A Russian Experience. <i>AIDS and Behavior</i> , 2013, 17, 390-398.	2.7	20
64	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 74-80.	3.2	20
65	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Mortality. <i>Annals of Internal Medicine</i> , 2019, 170, 430.	3.9	20
66	“No home to take methadone to” Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108655.	2.8	20
67	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 19-22.	0.9	19
68	Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 150-159.	1.2	19
69	Chronic Opioid Therapy in People Living With Human Immunodeficiency Virus: Patients' Perspectives on Risks, Monitoring, and Guidelines. <i>Clinical Infectious Diseases</i> , 2019, 68, 291-297.	5.8	19
70	Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study—a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. <i>HIV Research and Clinical Practice</i> , 2019, 20, 48-63.	1.1	18
71	Factors associated with help seeking by community responders trained in overdose prevention and naloxone administration in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107531.	3.2	18
72	Assessing pharmacy-based naloxone access using an innovative purchase trial methodology. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 853-860.	1.5	18

#	ARTICLE	IF	CITATIONS
73	Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e2052-e2058.	5.8	18
74	Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 740-749.	1.5	17
75	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	5.9	17
76	Postpartum changes in methadone maintenance dose. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 229-232.	2.8	16
77	Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs. <i>Substance Abuse</i> , 2019, 40, 441-443.	2.3	16
78	Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 824-831.	1.5	16
79	A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care. <i>Aids</i> , 2019, 33, 1467-1476.	2.2	16
80	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. <i>International Journal of Drug Policy</i> , 2020, 85, 102602.	3.3	16
81	Inpatient addiction consultation and post-discharge 30-day acute care utilization. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108081.	3.2	16
82	Are Opioid Dependence and Methadone Maintenance Treatment (MMT) Documented in the Medical Record? A Patient Safety Issue. <i>Journal of General Internal Medicine</i> , 2009, 24, 1007-1011.	2.6	15
83	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. <i>Medical Care</i> , 2022, 60, 256-263.	2.4	15
84	Age-based preferences for risk communication in the fentanyl era: "A lot of people keep seeing other people die and that's not enough for them". <i>Addiction</i> , 2021, 116, 1495-1504.	3.3	14
85	Characteristics of post-overdose public health-public safety outreach in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108499.	3.2	14
86	Competing risks of women and men who use fentanyl: "The number one thing I worry about would be my safety and number two would be overdose". <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108313.	2.8	14
87	Identification of non-steroidal anti-inflammatory drug use disorder: A case report. <i>Addictive Behaviors</i> , 2017, 70, 61-64.	3.0	13
88	Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 1-10.	2.8	13
89	Opioid and cocaine use among primary care patients on buprenorphine "Self-report and urine drug tests. <i>Drug and Alcohol Dependence</i> , 2018, 192, 245-249.	3.2	13
90	Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1518-1529.	2.4	13

#	ARTICLE	IF	CITATIONS
91	Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1140-1144.	1.2	13
92	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	2.8	13
93	Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. <i>Drug and Alcohol Dependence</i> , 2021, 224, 108703.	3.2	13
94	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	3.3	13
95	Sexually transmitted infections among HIV-infected heavy drinkers in St Petersburg, Russia. <i>International Journal of STD and AIDS</i> , 2012, 23, 853-858.	1.1	12
96	Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia. <i>PLoS ONE</i> , 2016, 11, e0166539.	2.5	12
97	HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. <i>AIDS and Behavior</i> , 2017, 21, 2618-2627.	2.7	12
98	Public restrooms and the opioid epidemic. <i>Substance Abuse</i> , 2020, 41, 432-436.	2.3	12
99	Warrant checking practices by post-overdose outreach programs in Massachusetts: A mixed-methods study. <i>International Journal of Drug Policy</i> , 2022, 100, 103483.	3.3	12
100	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. <i>AIDS and Behavior</i> , 2008, 12, 662-669.	2.7	11
101	Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1013-1018.	1.2	11
102	Older, hypertensive, and hypercholesterolemic fairgoers visit more booths and differ in their health concerns at a community health fair. <i>Journal of Community Health</i> , 2000, 25, 315-329.	3.8	10
103	Which patients receive an addiction consult? A preliminary analysis of the INREACH (INpatient) Tj ETQq1 1 0.784314 rgBT /Overlock 10 35-42.	2.8	10
104	Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 507-515.	1.2	10
105	Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. <i>International Journal of Drug Policy</i> , 2021, 98, 103400.	3.3	10
106	Integration of substance use treatment and medical care: A special issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 377-381.	2.8	9
107	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. <i>AIDS and Behavior</i> , 2015, 19, 1089-1097.	2.7	9
108	Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 195-201.	2.1	9



#	ARTICLE	IF	CITATIONS
109	Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 2418-2426.	2.6	9
110	Pharmacy leaders'™ beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1493-1497.	3.0	9
111	Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. <i>Health Affairs</i> , 2022, 41, 434-444.	5.2	9
112	Frequency and associated risk factors of non-fatal overdose reported by pregnant women with opioid use disorder. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 26.	2.6	8
113	Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome. <i>Hospital Pediatrics</i> , 2019, 9, 576-584.	1.3	8
114	Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug'™ and Non'™Injection Drug'™Associated Endocarditis. <i>Clinical Infectious Diseases</i> , 2020, 71, 480-487.	5.8	8
115	Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 304-310.	1.5	8
116	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109190.	3.2	8
117	Community'™based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	3.3	8
118	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2011, 26, 77-82.	2.6	7
119	The Surgeon General's Facing Addiction report: An historic document for health care. <i>Substance Abuse</i> , 2017, 38, 122-122.	2.3	7
120	Predicting longitudinal service use for individuals with substance use disorders: A latent profile analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108632.	2.8	7
121	Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109259.	3.2	7
122	Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 39, 114-120.	3.3	6
123	Pharmacists'™ experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 157-166.	1.5	6
124	Integrating substance use care into primary care for adolescents and young adults: Lessons learned. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108376.	2.8	6
125	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. <i>Journal of Addiction Medicine</i> , 2014, 8, 164-169.	2.6	5
126	Federal Policymakers Should Urgently and Greatly Expand Naloxone Access. <i>American Journal of Public Health</i> , 2022, 112, 558-561.	2.7	5



#	ARTICLE	IF	CITATIONS
127	Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 546-552.	2.1	5
128	[Commentary] CAN ONE BE AN EXPERT IN ADDICTION MEDICINE WITHOUT EXPERTISE IN PAIN MANAGEMENT?. Addiction, 2008, 103, 2006-2007.	3.3	4
129	2012 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice, 2013, 8, 6.	2.6	4
130	HIV prevention and treatment strategies can help address the overdose crisis. Preventive Medicine, 2015, 80, 37-40.	3.4	4
131	It could potentially be dangerous... but nothing else has seemed to help me. Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. Journal of Substance Abuse Treatment, 2021, 131, 108455.	2.8	4
132	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction, 2022, , .	3.3	4
133	2013 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice, 2013, 8, 18.	2.6	3
134	Intranasal Naloxone for Opioid Overdose Reversal. Prehospital Emergency Care, 2015, 19, 135-137.	1.8	3
135	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction, 2022, 117, 2450-2461.	3.3	3
136	If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. BMC Public Health, 2022, 22, 735.	2.9	3
137	The Patients in Recovery (PIR) Perspective: Teaching Physicians about Methamphetamine. Substance Abuse, 2008, 29, 61-64.	2.3	2
138	Preventing Prescription Opioid Overdose Deaths. Journal of General Internal Medicine, 2013, 28, 1258-1259.	2.6	2
139	Massachusetts Health Reform's Effect on Hospitalizations with Substance Use Disorder-Related Diagnoses. Health Services Research, 2018, 53, 1727-1744.	2.0	2
140	Alcohol and Bone Turnover Markers among People Living with HIV and Substance Use Disorder. Alcoholism: Clinical and Experimental Research, 2020, 44, 992-1000.	2.4	2
141	Opioid Overdose Fatality Prevention Reply. JAMA - Journal of the American Medical Association, 2013, 309, 873.	7.4	1
142	Comments on Strang et al. (2016): "Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?"™. Addiction, 2016, 111, 1879-1880.	3.3	1
143	Response to Letter to the Editor: The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. Public Health Reports, 2020, 135, 542-543.	2.5	1
144	Emergency Department Utilization Among People Living With HIV on Chronic Opioid Therapy. Journal of the International Association of Providers of AIDS Care, 2021, 20, 232595822110109.	1.5	1

#	ARTICLE	IF	CITATIONS
145	Treatment of Refractory Opioid Use Disorder. Journal of General Internal Medicine, 2021, 36, 1793-1793.	2.6	1
146	Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. Aids, 2021, 35, 697-700.	2.2	1
147	In reply:. Annals of Emergency Medicine, 2020, 75, 553-554.	0.6	0
148	SUN-540 No Effect Of Alcohol Use On Bone Microarchitecture Of The Distal Radius Among HIV Infected Adults. Journal of the Endocrine Society, 2019, 3, .	0.2	0
149	A collaborative care intervention to improve opioid prescribing among providers caring for persons with HIV: Impact on satisfaction, confidence, and trust. Drug and Alcohol Dependence, 2022, 231, 109250.	3.2	0
150	Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications. AIDS and Behavior, 0, , .	2.7	0